Ross Muken
Stock Analyst at Evercore ISI Group
(2.05)
# 2,895
Out of 4,876 analysts
40
Total ratings
57.14%
Success rate
1.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: In-Line | $190 → $225 | $150.01 | +49.99% | 6 | Nov 7, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $360 → $350 | $144.56 | +142.11% | 7 | Oct 8, 2024 | |
| HSIC Henry Schein | Maintains: In-Line | $70 → $74 | $73.27 | +1.00% | 8 | Oct 8, 2024 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $119.17 | +9.09% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $47.77 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $167.18 | -59.92% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $94.79 | +163.74% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $408.28 | -46.12% | 1 | Jan 4, 2018 | |
| MBLY Mobileye Global | Downgrades: In-Line | n/a | $18.34 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Nov 7, 2024
Maintains: In-Line
Price Target: $190 → $225
Current: $150.01
Upside: +49.99%
ICON Public Limited Company
Oct 8, 2024
Maintains: Outperform
Price Target: $360 → $350
Current: $144.56
Upside: +142.11%
Henry Schein
Oct 8, 2024
Maintains: In-Line
Price Target: $70 → $74
Current: $73.27
Upside: +1.00%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $119.17
Upside: +9.09%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $47.77
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $167.18
Upside: -59.92%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $94.79
Upside: +163.74%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $408.28
Upside: -46.12%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $18.34
Upside: -